The future of longevity: innovation, safety and responsibility

Around longevity an enormous market has formed, and together with the market a gray area has grown where serious protocols and unfounded promises present themselves with the same language.

At Image Regenerative, in Milano and St. Moritz, this is the difficulty we encounter most often at initial consultation: people arrive with information collected everywhere, unable to distinguish what is proven from what is merely suggestive.

We discussed this when addressing new frontiers of longevity beyond biohacking, and it is why it is worth providing a method of judgment, even before a list of treatments.

Innovation and longevity: where we stand

The growth of this field is documented and impressive. Scientific publications dedicated to longevity have increased from just over one thousand at the beginning of the century to over nine thousand in 2025, while those on applied technologies have grown from a few dozen to over one thousand five hundred in the same period.

The economic counterpart has equally significant dimensions: the European silver economy is worth approximately five thousand seven hundred billion euros. Within the ecosystem of companies developing technologies for aging, the largest share works on artificial intelligence and predictive analysis of health data, while a substantial portion operates in genomics and precision medicine.

This abundance is good news in terms of research and a problem in terms of orientation. The speed with which initial results reach the public has exceeded the speed at which they are validated, and it happens that a molecule studied in animal models is presented as available before a clinical trial on humans even exists. The gap between what is promising and what is proven is today the real terrain on which the credibility of the discipline is played out.

The way this content circulates also contributes to the phenomenon. Biohacking, born as a niche practice, has become a matter of columns and daily conversation, and in the transition it has lost the methodological references that made sense in the original context. A protocol that a person applies to themselves, measuring their own parameters and consciously accepting the risks, changes completely in nature when proposed to a wide audience as a general recommendation. The distance between personal experimentation and clinical indication is exactly what responsible communication should make explicit, and which instead is almost always left implicit.

Safety first: the role of evidence

In longevity medicine the safety issue has a particular characteristic that distinguishes it from acute disease medicine: the recipient is well.

When treating a healthy person, the acceptable risk margin drops drastically. In a serious illness a significant adverse effect may be a reasonable price for a proportionate benefit; in a preventive intervention on someone without symptoms, that same adverse effect is simply damage produced without necessity. It is reasoning that should precede any therapeutic proposal in this field.

Evidence is built in stages, and knowing this hierarchy helps place what one reads:

• A laboratory study or animal model indicates a plausible direction.

• An observational study on human groups shows associations, which do not equate to causal relationships.

• A controlled clinical trial verifies whether an intervention actually produces the expected effect compared to a control.

• Systematic reviews collect and weigh the entirety of available data.

Presenting a result from the first level with the language of the last is the most widespread form of distortion in longevity communication.

A point regarding timing should be added. An intervention designed to act over decades would require decades of observation to be fully evaluated, and this structural asymmetry will accompany the field for a long time. Recognizing it is more useful than feigning a certainty that the data do not yet offer.

Caution must then be calibrated to the individual. Those taking multiple medications simultaneously, those living with a chronic condition, those with reduced kidney or liver function, and those who are pregnant or breastfeeding require a higher threshold of prudence, because in these conditions interactions become more likely and less predictable. This is why a generally valid recommendation may be completely inappropriate in the specific case, and why medical history retains a weight that no diagnostic technology has reduced.

Promising therapies and proven therapies

The distinction between the two categories can be made with concrete criteria, verifiable even by those without medical training.

An example of a complete validation pathway is that of Lipogems® technology, which uses autologous micro-fragmented adipose tissue: patented by Prof. Carlo Tremolada in 2010, it has obtained FDA cleared classification and is documented in peer-reviewed literature, as in the narrative review on micro-fragmented adipose tissue dedicated to this therapeutic approach. The difference from a proposal lacking these steps is verifiable by anyone, and lies entirely in the availability of consultable documentation.

The responsibility of physician and patient

Responsibility in this field is shared, and the two parties have different tasks.

The physician has the duty to distinguish what they know from what they hypothesize, and to say so. Transparency about the limits of every proposal belongs to them, the willingness to advise against a treatment that would bring marginal benefit, and the ability to recognize when the correct answer belongs to another specialist. In our team's experience, telling a person that the intervention they request is not needed is a clinical act in every respect, and often the most useful of the entire consultation.

The person, on the other hand, has an active role that goes beyond formal consent. It means fully declaring ongoing therapies and supplements, including substances purchased independently, because interactions exist even with products perceived as harmless. It means asking questions about available alternatives and the consequences of doing nothing. Finally, it means maintaining proportionate expectations: longevity is built with the continuity of daily behaviors, and no protocol compensates for their absence.

There is also a responsibility that concerns those who communicate. Presenting partial results as definitive acquisitions produces damage that goes beyond the individual case, because it feeds a generalized distrust that ends up affecting solid therapies as well.

A less visible form of responsibility finally concerns people's time and money. Every path undertaken on fragile bases subtracts resources from interventions that would have produced greater benefit, and above all subtracts that time window in which prevention works best. It is a cost that rarely appears in the balance of a therapeutic choice, while in clinical practice it is observed regularly: people who arrive after years of inconclusive protocols, having neglected in the meantime the daily habits on which most of the obtainable result rests.

Regulation and access to new therapies

The regulatory framework moves more slowly than research, and this asynchrony generates the most concrete problems.

On one hand rigorous regulation protects people, requiring that a treatment demonstrate safety and efficacy before reaching the public. On the other, long authorization times slow access to therapies that could bring real benefits. The proposal circulating in European circles to reduce this tension concerns so-called regulatory sandboxes, that is, controlled environments in which to experiment with innovations by reducing times without giving up surveillance.

A separate chapter concerns supplements, which in Europe are regulated as foods and never as medicines. The practical consequence is that the manufacturer is responsible for the product's safety without having to demonstrate therapeutic efficacy, and that health claims are only permitted in authorized form. A supplement may therefore legitimately claim to contribute to normal energy metabolism, while attributing to it the ability to slow aging falls outside the permitted scope. Recognizing this difference in language helps read labels for what they actually claim.

The flip side is medical tourism to countries with permissive regulations, where treatments lacking authorization in Europe are offered. The cost of this choice is measured in the lack of protections in case of complications and the absence of follow-up care upon return, when any problems manifest far from those who caused them.

Finally, the issue of equity in access remains. If the most advanced tools remain the prerogative of a few, longevity medicine risks widening health inequalities instead of reducing them. It is a theme that concerns health policies more than individual facilities, and that deserves to be named instead of ignored. It must be said that the most effective part of a longevity pathway coincides with very low-cost interventions, from regular movement to sleep quality, and this mitigates the problem without completely resolving it.

How to navigate between innovation and prudence

The practical synthesis lies in a few operational indications.

The first is to verify that the foundations are solid before adding anything. Regular movement, adequate sleep, balanced nutrition, stress management, absence of smoking, and social relationships are the interventions with the best ratio between evidence and cost, and no technology replaces them.

The second is to demand individual evaluation. An identical protocol for everyone is a commercial product, while a medical pathway starts from an evaluation of the individual and modifies itself based on what emerges.

The third is to distrust the language of certainties. In medicine we work with probabilities and margins of improvement: those who promise guaranteed outcomes are speaking a language that clinical practice does not know.

The fourth is to always ask what happens if one chooses not to intervene. It is the question that unmasks proposals built on induced need, and the answer received says much about the interlocutor's honesty.

Innovation in this field is real and destined to profoundly modify medicine in the coming decades. Treating it with prudence does not mean refusing it: it means demanding that every step forward be accompanied by the evidence that justifies it.

Frequently asked questions

How do I understand if a longevity therapy is serious?

By verifying four elements. That clinical studies on humans exist and not only laboratory data or testimonials. That the technology declares recognized validation or certification. That results are published in peer-reviewed journals, independent of those selling the product. That those proposing it also describe limitations, contraindications and adverse effects, and not only expected benefits.

Does "natural" mean safe?

No. The natural origin of a substance says nothing about its safety, appropriate dosage or interactions with other therapies. Many active ingredients used in pharmacology derive from natural sources and present significant adverse effects. Safety depends on available documentation, production quality, dosage and the medical context in which the substance is used.

Why distrust those who promise certain results?

Because medicine works with probabilities and not certainties. Response to a treatment depends on individual variables that no evaluation completely eliminates, so no outcome is guaranteed. Clinically correct communication speaks of support, reduction, improvement over time, and always accompanies the indication with limitations and possible adverse effects.

What questions should I ask the physician?

Four are particularly useful. What evidence supports this proposal in my specific case. What are the possible risks and adverse effects. What alternatives exist, including less expensive ones. What happens if I choose to do nothing and simply monitor the situation. The quality of the answers is already a criterion for evaluating the interlocutor.